- BriaCell Therapeutics (TSXV:BCT) and ImaginAB have entered a collaboration to evaluate advanced breast cancer with immunotherapy imaging technology
- BriaCell will use ImaginAB’s CD8 ImmunoPET imaging technology in order to see the entire body to visualize tumor-attacking CD8 T cells
- This will be used in BriaCell’s ongoing Phase I/IIa study with Incyte in metastatic or locally recurrent breast cancer patients
- Under the terms of the agreement ImaginAB will receive license fees and payments for providing ongoing technical, clinical and regulatory support in order to facilitate successful implementation of its CD8 ImmunoPET technology
- Shares of BriaCell Therapeutics are 0.14 per cent to C$7.15 as of 11:21 a.m. EDT
BriaCell Therapeutics (BCT) has entered into a collaboration with ImaginAB to evaluate advanced breast cancer with an immunotherapy imaging technology.
The multi-year non-exclusive license agreement will have ImaginAB supply clinical doses of its CD8 ImmunoPET technology to BriaCell to be used in BriaCell’s study in its ongoing Phase I/IIa study.
The study, which is currently underway with Incyte, is with patients who have metastatic or locally recurrent breast cancer.
Under the terms of the agreement, ImaginAB will receive license fees and payments for providing ongoing technical, clinical and regulatory support for implementing its CD8 ImmunoPET technology.
This technology provides whole body visualization of increased CD8 T cells, specifically those that attack tumors.
“ImaginAb’s cutting edge CD8 ImmunoPET technology has been used by leading cancer drug developers to more accurately analyze tumors and immune responses to cancer treatments,” Dr. Bill Williams, president and CEO of BriaCell, said in a press release. “We look forward to working with the team of experts at ImaginAb to evaluate the safety and efficacy of BriaCell’s immunotherapy treatments in patients with advanced breast cancer.”
This is the first time ImaginAb’s ImmunoPET technology — also called 89Zr-Df-Crefmirlimab — will be used to image the response of breast cancer.
“We are excited about the benefits 89Zr-Df-Crefmirlimab can potentially bring to patients and how it could help BriaCell accelerate the development of its novel immunotherapy treatments,” Ian Wilson, CEO of ImaginAb, said in the release.
With headquarters in Vancouver and New York, BriaCEll is an immuno-oncology biotechnology company that is developing targeted approaches to manage cancer.
The company currently has a non-exclusive clinical trial collaboration with Incyte to evaluate the effects of combinations of novel clinical candidates.
Shares of BriaCell Therapeutics are 0.14 per cent to C$7.15 as of 11:21 a.m. EDT.
